Mixed medicine offers relief for Hong Kong patients with breathing problems
Advertisement
The Hospital Authority said the pilot scheme targeting respiratory diseases had started at Haven of Hope Hospital in Tseung Kwan O in April last year and was now available at Kowloon, Ruttonjee and Grantham hospitals.
'This scheme targets patients aged 18 or above who have been diagnosed with asthma, bronchiectasis or chronic obstructive pulmonary disease, and experience persistent respiratory symptoms,' said Rowena Wong How-wan, the authority's chief manager of Chinese medicine.
'After an assessment by doctors and Chinese medicine practitioners in our team, we will invite eligible patients to join the voluntary scheme. The fee for each treatment session is HK$120 [US$15.80].'
The Integrated Chinese-Western Medicine Programme now involves 26 hospitals providing stroke care, musculoskeletal pain management, cancer palliative care, cancer care, knee osteoarthritis management and respiratory disease management.
Advertisement
Dr Wong Wei-ying, deputy chief executive of Haven of Hope Hospital, said that as of the end of last month, 120 patients, aged 38 to 96, had taken part in the pilot scheme for respiratory diseases. Their average age was 75, with a male-to-female ratio of 3-1.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
RTHK
4 days ago
- RTHK
Settlement reached over Covid-19 vaccines
Settlement reached over Covid-19 vaccines The Pfizer-BioNTech vaccine was the first mRNA vaccine approved for use and the first Covid vaccine to receive approval in the West. File photo: RTHK American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain's GSK and Germany's CureVac US$740 million plus royalties to settle US legal disputes over Covid-19 vaccines, CureVac said on Friday. The royalties would amount to a "single-digit" percentage on sales of Covid-19 vaccines in the United States, CureVac said. The German firm added that it would grant Pfizer and BioNTech the non-exclusive licence to make and sell mRNA-based Covid and flu products in the United States. GSK, which has worked with CureVac since 2020 to develop mRNA vaccines for infectious diseases, said that it would receive US$370 million as well as a 1 percent royalty on US sales of flu, Covid and "related combination mRNA vaccine products". CureVac sued German rival BioNTech in 2022, arguing that it had infringed patents relating to mRNA technology in making its blockbuster Comirnaty coronavirus vaccine in collaboration with Pfizer. Unlike traditional vaccines that contain some form of the dead or inactivated target virus, mRNA vaccines contain genetic materials that instruct human cells to make proteins typical of the targeted virus. Since the virus need not be grown in the lab, mRNA vaccines can in theory be developed at scale more quickly than conventional vaccines. The Pfizer-BioNTech vaccine was the first mRNA vaccine approved for use and the first Covid vaccine to receive approval in the West. CureVac's own efforts to make an mRNA-based Covid vaccine during the pandemic did not come to fruition. The deal brings the dispute between CureVac and BionNTech to an end ahead of the planned acquisition of CureVac by BioNTech, announced in June. CureVac and BioNTech are still locked in legal disputes in Germany but CureVac said the deal "set a framework for resolving ongoing patent disputes outside the US". In March, a German court sided with American pharmaceutical firm Moderna in its claim that BioNTech and Pfizer had broken one of its patents in making its Covid-19 vaccine. (AFP)
HKFP
5 days ago
- HKFP
Hong Kong records 3 more chikungunya fever infections, as expert warns of steady increase in imported cases
Hong Kong's health authorities have recorded three more imported cases of the mosquito-borne chikungunya fever, including an elderly woman who returned from Foshan, the mainland Chinese city that has emerged as a hotspot for the virus. The three new cases were reported by the Centre for Health Protection (CHP) on Wednesday evening, bringing the total in Hong Kong to four. Among them was a 79-year-old woman living in Southern District. She developed a fever and joint pain on Monday and was admitted to Queen Mary Hospital the next day, where she is in stable condition. The patient travelled to Foshan, in nearby Guangdong province, to visit relatives in July, but did not recall getting bitten by mosquitoes there. As she stayed in Foshan for most of the incubation period, the CHP considered that she was infected while travelling. The other two cases reported on Wednesday involved a 55-year-old man and his son, aged 10, living in Kwai Tsing. They travelled to Bangladesh between July 12 and August 3, and both developed fever and joint pain while they were still abroad. Both are now in Princess Margaret Hospital and are in stable condition. Their household contacts are currently asymptomatic and are under medical surveillance. Hong Kong's first imported case of the virus was reported last Saturday, involving a 12-year-old boy who returned from Foshan last month. The Food and Environmental Hygiene Department (FEHD) has taken mosquito extermination and prevention measures near the patients' homes and other places they have visited. Health authorities in Foshan, Guangdong province have recorded more than 7,000 confirmed cases. More infections expected The Head of the Communicable Disease Branch of the CHP, Albert Au, reminded members of the public to adopt precautions against mosquito-borne diseases in this rainy season. And speaking on RTHK on Thursday, infectious disease expert Joseph Tsang said more infections could be expected given the 'frequent exchanges' between Hong Kong and Guangdong. 'Chikungunya fever hasn't become endemic, but whether it will become unstoppable in the future depends on future developments,' Tsang said in Cantonese. Tsang, who is co-chair of the Hong Kong Medical Association's advisory committee on communicable diseases, also said residents should refrain from visiting high-risk areas and not just rely on authorities' control measures. The mosquito-borne virus should not be underestimated, he added, as it could leave patients with chronic arthritis. According to the CHP, Hong Kong saw between one and 11 chikungunya infections each year from 2016 to 2019. The FEHD has urged residents to carry out mosquito prevention and control measures including changing water in vases, removing water in saucers under potted plants at least once a week, and properly disposing of containers such as soft drink cans and lunch boxes. Separately, microbiologist Yuen Kwok-yung, who advised the Hong Kong government's Covid-19 response during the pandemic, told local media that the infections were within expectations given the number of people in Hong Kong who travel to mainland China for holiday.
South China Morning Post
5 days ago
- South China Morning Post
US firm says it made Hong Kong student's award-winning app ‘from scratch'
A US-based software development agency has said it was commissioned by the mother of a Hong Kong student to build from scratch a medication prescription app that was later submitted to academic competitions under the pupil's name without its consent. Advertisement Ahmed Jemaa, co-founder of US-based AI Health Studio, said the company was not told that the MediSafe app it created would be submitted to the contests and argued the move was unfair to other student participants. He also accused the mother of attempting to 'control the narrative' after controversy broke out in June over whether her daughter was the sole inventor of the award-winning project. In a social media post earlier in the week, Jemaa named his client as Roberta Pang, who is the wife of Ronnie Poon Tung-ping, owner of the Hepatobiliary-Pancreatic & Colorectal Surgery Centre. He said she had commissioned his team between March 2024 and June this year to develop MediSafe. Their daughter, a Form Four student from St Paul's Co-educational College in Mid-Levels, has submitted the app in competitions as her invention and has won eight awards in global contests. Advertisement Jemaa said MediSafe was a prototype designed to simulate prescription safety checks, flagging drug-to-drug interactions, allergy contraindications and warnings for renal or hepatic risks.
